How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Malignancy marker for therapy planning

Organization name

PROvendis GmbH

Profile

The diagnosis, classification and therapy of prostate cancer are based on the PSA value, the Gleason score from histology obtained by prostate biopsies and an imaging diagnosis from CT and bone scintigraphy. The variability of prostate cancer ranges from low-risk tumors without progression over many years to high-risk tumors with rapid local progression and high metastasis potential. There is a correlation with the risk for metastasis and the Gleason score, however there is an ongoing search for new biomarkers that directly correlate with the risk for metastasis.

Vimentin 3 (Vim3) has been discovered as biomarker, which correlates with the risk of progression of prostate cancer. Results show high expression of Vim3 in cells of metastatic prostate and low expression in non-metastatic cancer, thus demonstrating the potential of Vim3 for risk stratification of localized prostate carcioma to enable personalized therapy planning.

Vim3 is a truncated and biologically active variant of Vimentin. Healthy cells express the Vimentin full-length variant (Vim-fl) and are characterized by a functional cytoskeleton. If Vim-fl is no longer expressed in the cells, Vim3 is predominantly detectable. In this case the intracellular structure of the cell is disordered due to the loss of the normal cytoskeletal architecture with the consequence that cells become deformable and consequently mobile.

Commercial Opportunities

Prostate cancer is the second most common cancer in males. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, accounting for 15% of the cancers diagnosed in males. The selection of the therapeutic strategy depends on the risk classification. There is a strong medical need to precisely identify those patients whose disease allows monitoring without therapeutic intervention, in order to avoid overtreatment, which comes along with high medical costs and loss of life quality.

Current Status

To date, 200 serum samples from prostate cancer patients, resectates and biopsies have been examined. A validation on about 800 serum samples is planned. Data on additional tumor types are available, including urethel cancer and breast cancer. In case of interest we are pleased to inform you about the patent status.

Relevant Publication

Von Brandenstein, M. et al. (2018) Tamoxifen Treatment in Correlation with Increased ET-1 Levels Is Associated with the Development of Breast Cancer Metastases. Journal of Cancer Therapy 9: 438-436; Von Brandenstein, M. et al. (2018) Beyond the 3’UTR binding: microRNA - induced protein truncation via DNA binding, Oncotarget 9: 32855-32867.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback to "Malignancy marker for therapy planning"

  

latest entries

latest entries